Drug Profile

PB 4001

Alternative Names: Ceraxa I/O #1; PB-4001

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PendreaBio
Class Antineoplastics; Ceramides; Immunotherapies; Sphingolipids
Mechanism of Action Apoptosis stimulants; Cytotoxic T lymphocyte stimulants; Undecaprenyl pyrophosphate synthetase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

02 Feb 2025 PB 4001 is available for licensing as of 02 Feb 2025. https://www.pendreabio.com/copy-of-rna-therapeutics
02 Feb 2025 Early research in Cancer in USA (unspecified route) prior to January 2025 (PendreaBio Pipeline, January 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com